Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT2B17 | O75795 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.31 |
| ▸ | ELAVL1 | Q15717 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14885013 | 0.95 | UGT2B17 (0.44) | UGT2B17ACHECHRM4HTTUHRF1 | |
| SCHEMBL10286322 | 0.94 | UGT2B17 (0.43) | UGT2B17ACHECHRM4HTTUHRF1 | |
| SCHEMBL527248 | 0.83 | UGT2B17 (0.50) | UGT2B17ACHECHRM4HTTUHRF1 | |
| SCHEMBL10286080 | 0.81 | UGT2B17 (0.44) | UGT2B17ACHEHTTUHRF1ELAVL1 | |
| SCHEMBL10286287 | 0.79 | UGT2B17 (0.42) | UGT2B17ACHEHTTUHRF1KDM4E | |
| SCHEMBL10286284 | 0.79 | UGT2B17 (0.42) | UGT2B17ACHEHTTUHRF1KDM4E | |
| SCHEMBL10286371 | 0.79 | UGT2B17 (0.42) | UGT2B17ACHEHTTUHRF1KDM4E | |
| SCHEMBL526851 | 0.79 | ACHE (0.44) | UGT2B17ACHEHTTUHRF1KDM4E | |
| SCHEMBL10286309 | 0.79 | ACHE (0.48) | UGT2B17ACHECHRM4HTTUHRF1 | |
| SCHEMBL10286333 | 0.79 | UGT2B17 (0.45) | UGT2B17ACHECHRM4HTTUHRF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130102631-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102631-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2013-04-25 | — | — | US | disclosed |
| WO-2012001040-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102631-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | MSR1, DDT, MPO | UGT2B17 1446/4885ACHE 660/4885CHRM4 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.